Skip to main content
. 2011 Sep 7;22(3):327–338. doi: 10.1007/s10165-011-0516-6

Fig. 2.

Fig. 2

Time course of disease activity over 52 weeks following initiation of adalimumab treatment. Data were analyzed by the last observation carried forward (LOCF) method. a All patients (n = 167), b previous biologics (+, left) (n = 49) and (−, right) (n = 118), and c concomitant MTX (+, left) (n = 143) and (−, right) (n = 24). Disease activity was categorized as follows Inline graphic